Is Crinetics Pharmaceuticals Inc (CRNX) a risky stock?
As of July 21, 2026, Clavix grades Crinetics Pharmaceuticals Inc (CRNX) B- for risk, a composite score of 63 out of 100 on an A+ to F scale, which puts CRNX in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind CRNX's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how CRNX scores on each, as of July 21, 2026.
What's moving CRNX's risk right now
Company-specific signals Clavix flags behind CRNX's current grade, drawn from recent news and filings as of July 21, 2026.
An external legal investigation is underway involving CRNX, which could signal concerns about corporate governance, securities practices, or pending transactions that may affect s…
CRNX shareholders will receive a cash buyout at $85 per share, effectively removing the stock as an independent traded entity and providing certainty of value, after which the sto…
For CRNX shareholders, this acquisition validates the company's pipeline and provides a definitive exit at a premium; for Vertex, the deal signals a major capital deployment to re…
What a B- grade means
On the Clavix A+ to F scale, CRNX's composite of 63 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell CRNX or any security. Grades are risk indicators, not predictions of return. Data may be delayed.